Cargando…
Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019
IMPORTANCE: Despite the political salience of insulin prices, no study to date has quantified trends in insulin prices that account for manufacturer discounts (net prices). OBJECTIVE: To describe trends in insulin list prices and net prices faced by payers from 2012 to 2019 and estimate changes in n...
Autores principales: | Dickson, Sean, Gabriel, Nico, Gellad, Walid F., Hernandez, Inmaculada |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276305/ https://www.ncbi.nlm.nih.gov/pubmed/37327008 http://dx.doi.org/10.1001/jamahealthforum.2023.1430 |
Ejemplares similares
-
Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019
por: Dickson, Sean R., et al.
Publicado: (2023) -
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
por: Dickson, Sean, et al.
Publicado: (2022) -
Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
por: San-Juan-Rodriguez, Alvaro, et al.
Publicado: (2019) -
Trends in Proportion of Medicare Part D Claims Subject to 340B Discounts, 2013-2020
por: Dickson, Sean, et al.
Publicado: (2023) -
Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors
por: San-Juan-Rodriguez, Alvaro, et al.
Publicado: (2021)